Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07608003
Recruiting Observational

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

NCT07608003 · tracked via the Priya Life Science China tracker
Sponsor
Xiangya Hospital of Central South University
Phase
Observational
Started
2026-05-10
Last updated
2026-05-27

Condition(s) studied

Gliomas Harboring IDH1 and/or IDH2 MutationsGlioma Glioblastoma MultiformeGlioma of BrainstemGlioma, Diffuse Midline, H3K27M-mutantGlioma : Oligodendroglioma or AstrocytomaGliomas

Study summary

A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p/19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with diffuse gliomas were pathologically and molecularly diagnosed. * The clinical case data of all patients were complete. * Patients underwent preoperative MRI examination. Exclusion Criteria: * The tumor is not located in the intracranial midline. * Cases in which MRI were incomplete or with significant noise and artifacts.

Primary outcome measure(s)

  • Diagnostic accuracy for midline glioma molecular subtypes — Perioperative
    Model predictions compared with postoperative histopathology and molecular testing (gold standard). Performance metrics include AUC, F1 score, sensitivity, specificity, and accuracy.

Trial sites (1)

FacilityCityRegionStatus
Xiangya Hospital of Central South University Changsha Hunan Recruiting

More Xiangya Hospital of Central South University trials in China

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST Recruiting
RET-Targeted Molecular Imaging Probes in Prostate Cancer Active, not recruiting
Chinese ET Registry (CETR) Recruiting
Microfocused Ultrasound for Facial Pigmentary Diseases and Rosacea Active, not recruiting
Preventive Effectiveness of Primary Care Physician-led CGM-supported Comprehensive Intervention on Cardio-metabolic-immune Diseases in Community Patients With Type 2 Diabetes (Community Diabetes Control Project) Starting soon

Other trials for the same condition

AI-assisted Diagnosis of Malignant Brain Tumors Recruiting
A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study) Active, not recruiting
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07608003 on ClinicalTrials.gov ↗ ← All trials in China